Results 211 to 220 of about 3,011 (240)

Editorial: Immune-checkpoint inhibitors and immunometabolic reprogramming in cancer immunotherapy. [PDF]

Front Immunol
Kumar V, De Falco V.
europepmc   +1 more source

Comparison of immune-related adverse events and analysis of risk factors in older and younger rectal cancer patients receiving immunotherapy. [PDF]

Am J Cancer Res
Liao J, Ye H, Wang J, Liu F, Zhu H, Xie G, Pan J.   +6 more
europepmc   +1 more source

Potential of interleukin-7 in sepsis as a biomarker and therapeutic agent: a narrative review. [PDF]

Front Med (Lausanne)
Zhang T, Liu H, Tie YF, Meng TW, Liang Q.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Distinct expression and inhibitory function of B and T lymphocyte attenuator on human T cells

Tissue Antigens, 2007
AbstractB and T lymphocyte attenuator (BTLA) has been recently identified as a new inhibitory receptor of the CD28 superfamily, with similarities to cytotoxic T lymphocyte activation antigen (CTLA)‐4 and programmed death (PD)‐1. Engagement of BTLA on T lymphocytes can profoundly reduce the T cell receptor (TCR)‐mediated activation.
X-F, Wang, Y-J, Chen, Q, Wang, Y, Ge, Q, Dai, K-F, Yang, , Fang-Xie, Y-H, Zhou, Y-M, Hu, Y-X, Mao, X-G, Zhang   +10 more
exaly   +3 more sources

B and T lymphocyte attenuator regulates the development of antigen-induced experimental conjunctivitis

Graefe's Archive for Clinical and Experimental Ophthalmology, 2011
To investigate the roles that B and T lymphocyte attenuator (BTLA) and herpesvirus entry mediator (HVEM) play in the development of antigen-induced experimental conjunctivitis (EC).BALB/c mice were immunized with ragweed (RW) in alum. Ten days later, the mice were challenged with RW in eye drops. After 24 hours, the conjunctivas, blood and spleens were
Hideo Yagita, Ken Fukuda, Atsuki Fukushima   +2 more
exaly   +3 more sources

Targeting B and T lymphocyte attenuator in cancer immunotherapy

International Journal of Biological Macromolecules
B and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor of B7 family that shares structural homology with cytotoxic T lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1). Overlapping BTLA binding sites in herpes virus entry mediator (HVEM) for different ligand/receptor interactions including CD160 and herpes simplex virus ...
Keywan Mortezaee
exaly   +3 more sources

B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator

Nature Immunology, 2004
B and T lymphocyte attenuator (BTLA) provides an inhibitory signal to B and T cells. Previously, indirect observations suggested that B7x was a ligand for BTLA. Here we show that BTLA does not bind B7x; instead, we identify herpesvirus entry mediator (HVEM) as the unique BTLA ligand.
Theresa Murphy, Coleman Lindsley, Kenneth Murphy   +2 more
exaly   +3 more sources

B and T lymphocyte attenuator (BTLA)

Science-Business eXchange, 2010
openaire   +2 more sources